The Global Molecular Glue Degrader Market Size is predicted to witness an 8.80% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- Growing demand for targeted protein degradation therapies is driving the molecular glue degrader market.
- Increasing investment in molecular glue startups is driving the molecular glue degrader market.
- North America dominated the market and accounted for a global revenue share in 2023.
- The molecular glue market faces challenges, including high product development costs and fluctuating worldwide raw material prices.
Molecular glue degraders offer a novel approach to drug development, as they bring together a target protein and an E3 ligase, leading to the degradation of the target protein. As traditional treatment options for these diseases become less effective, there is a growing need for innovative therapies that can target the underlying causes of these diseases. Additionally, the increasing investment is leading to a rapid expansion of the molecular glue degrader market, with new players joining the field and existing companies expanding their portfolios. This, in turn, leads to the rising development of new and innovative molecular glue degraders and more efficient and cost-effective manufacturing processes.
Finally, the rise of biotech and pharmaceutical companies investing in this area is another key market driver. Furthermore, companies recognize this technology's potential and invest in research and development to bring new molecular glue degraders to market.
Competitive Landscape:
Some of the Molecular Glue Degrader market players are:
- Proxygene GmbH
- Tories Bioscience,
- Life Sensors Inc
- Evotec SE
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- C4 Therapeutics, Inc.
- Seed Therapeutics, Inc.
- Rank Therapeutics Co. Ltd.
- Vanquish Therapeutics
Market Segmentation:
The molecular glue degrader market is segmented based on type, application and end users. The type segment includes PROteolysis Targeting Chimeras (PROTACs), Specific and Non-genetic IAP-dependent Protein ERasers (SNIPERs), Target ORiented ProtEin Degrader Optimizer (TORPEDO), Lysosomal Targeting Chimeras (LYTACs), and Others. By application, the market is segmented into cancer treatment, infectious diseases, genetic diseases, and others. By end users, the market is segmented into pharmaceutical and healthcare companies, Contract Research Organizations (CROs), and Contract Manufacturing Organizations (CMOs).
Based On Application, The Cancer Treatment Segment Is A Major Contributor To The Molecular Glue Degrader Market
The cancer treatment category is expected to hold a major share in the global Molecular Glue Degrader market in 2024. Cancer treatment is one of the key applications of molecular glue degraders. Cancer is a complex and heterogeneous disease; many cancer cells rely on specific proteins for their growth and survival. Molecular glue degraders offer a novel approach to cancer treatment by targeting these particular proteins and inducing their degradation, which can lead to cancer cell death. One of the advantages of using molecular glue degraders for cancer treatment is their ability to target previously "undruggable" proteins. Many cancer cells rely on these proteins for their growth and survival, but traditional drug development approaches have been unable to target them effectively.
PROTACs (PROteolysis TArgeting Chimeras) Segment Witnessed Growth At A Rapid Rate
The PROTACs (PROteolysis TArgeting Chimeras) segment is projected to grow rapidly in the global Molecular Glue Degrader market. PROTACs (PROteolysis TArgeting Chimeras) are a class of small molecules that can induce the degradation of specific proteins by the ubiquitin-proteasome system. They are designed as bifunctional molecules that consist of three parts: a ligand that binds to the target protein, a ligand that binds to an E3 ubiquitin ligase, and a linker that connects the two ligands.
The North American Molecular Glue Degrader Market Holds A Significant Regional Revenue Share
The North America Molecular Glue Degrader market is projected to register a tremendous market share in revenue soon. The US is known to be home to some of the world's largest biotech and pharmaceutical companies, which are investing heavily in developing new molecular glue degraders. The well-established research and development infrastructure in the United States provides a supportive environment for developing new drugs.
The favorable regulatory environment facilitates the approval and commercialization of new therapies. In addition, the Asia Pacific regional market is projected to grow rapidly in the global Molecular Glue Degrader market. Molecular glue degraders offer a promising approach to treating these diseases, and their potential to target previously "undruggable" proteins has generated significant interest in the markets in this region.
Recent Developments:
-
In May 2022, Evotec extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation. The collaboration has yielded a promising pipeline of molecular glue degraders, showcasing high productivity.
Molecular Glue Degrader Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 8.80% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Type, Application And End Users |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Proxygen GmbH, Tocris Bioscience, LifeSensors Inc., Evotec SE, Eli Lilly and Company, Bristol-Myers Squibb Company, C4 Therapeutics, Inc., Seed Therapeutics, Inc., Ranok Therapeutics Co. Ltd., Venquis Therapeutics |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
